KR102748728B1 - 유전성 혈관부종의 치료 방법 - Google Patents

유전성 혈관부종의 치료 방법 Download PDF

Info

Publication number
KR102748728B1
KR102748728B1 KR1020217043374A KR20217043374A KR102748728B1 KR 102748728 B1 KR102748728 B1 KR 102748728B1 KR 1020217043374 A KR1020217043374 A KR 1020217043374A KR 20217043374 A KR20217043374 A KR 20217043374A KR 102748728 B1 KR102748728 B1 KR 102748728B1
Authority
KR
South Korea
Prior art keywords
compound
dose
hae
administered
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020217043374A
Other languages
English (en)
Korean (ko)
Other versions
KR20220024220A (ko
Inventor
에드워드 폴 피너
샐리 루이즈 마시
안드레아스 메첼
미첼 데이비드 스미스
크리스토퍼 마르틴 예이
Original Assignee
칼비스타 파마슈티컬즈 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 칼비스타 파마슈티컬즈 리미티드 filed Critical 칼비스타 파마슈티컬즈 리미티드
Publication of KR20220024220A publication Critical patent/KR20220024220A/ko
Application granted granted Critical
Publication of KR102748728B1 publication Critical patent/KR102748728B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
KR1020217043374A 2019-06-14 2020-06-15 유전성 혈관부종의 치료 방법 Active KR102748728B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962861725P 2019-06-14 2019-06-14
US62/861,725 2019-06-14
GBGB1910116.1A GB201910116D0 (en) 2019-07-15 2019-07-15 Treatments of hereditary angioedema
GB1910116.1 2019-07-15
PCT/GB2020/051439 WO2020249977A1 (en) 2019-06-14 2020-06-15 Treatments of hereditary angioedema

Publications (2)

Publication Number Publication Date
KR20220024220A KR20220024220A (ko) 2022-03-03
KR102748728B1 true KR102748728B1 (ko) 2024-12-30

Family

ID=67700145

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217043374A Active KR102748728B1 (ko) 2019-06-14 2020-06-15 유전성 혈관부종의 치료 방법

Country Status (34)

Country Link
US (2) US20220218680A1 (cg-RX-API-DMAC7.html)
EP (2) EP3982960B1 (cg-RX-API-DMAC7.html)
JP (3) JP7356518B2 (cg-RX-API-DMAC7.html)
KR (1) KR102748728B1 (cg-RX-API-DMAC7.html)
CN (1) CN114126612A (cg-RX-API-DMAC7.html)
AR (1) AR119158A1 (cg-RX-API-DMAC7.html)
AU (1) AU2020293614B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021024664A2 (cg-RX-API-DMAC7.html)
CA (1) CA3142218A1 (cg-RX-API-DMAC7.html)
CL (2) CL2021003244A1 (cg-RX-API-DMAC7.html)
DK (1) DK3982960T3 (cg-RX-API-DMAC7.html)
EA (1) EA202193019A1 (cg-RX-API-DMAC7.html)
ES (1) ES2956471T3 (cg-RX-API-DMAC7.html)
FI (1) FI3982960T3 (cg-RX-API-DMAC7.html)
GB (1) GB201910116D0 (cg-RX-API-DMAC7.html)
HR (1) HRP20230696T1 (cg-RX-API-DMAC7.html)
HU (1) HUE063163T2 (cg-RX-API-DMAC7.html)
IL (1) IL288615A (cg-RX-API-DMAC7.html)
LT (1) LT3982960T (cg-RX-API-DMAC7.html)
MA (1) MA56187B1 (cg-RX-API-DMAC7.html)
MD (1) MD3982960T2 (cg-RX-API-DMAC7.html)
MX (1) MX2021014557A (cg-RX-API-DMAC7.html)
MY (1) MY205687A (cg-RX-API-DMAC7.html)
PH (1) PH12021552966A1 (cg-RX-API-DMAC7.html)
PL (1) PL3982960T3 (cg-RX-API-DMAC7.html)
PT (1) PT3982960T (cg-RX-API-DMAC7.html)
RS (1) RS64412B1 (cg-RX-API-DMAC7.html)
SG (1) SG11202113304YA (cg-RX-API-DMAC7.html)
SI (1) SI3982960T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202300261T1 (cg-RX-API-DMAC7.html)
TW (1) TW202112370A (cg-RX-API-DMAC7.html)
UA (1) UA129869C2 (cg-RX-API-DMAC7.html)
WO (1) WO2020249977A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202110685B (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201609607D0 (en) 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts
GB201719881D0 (en) 2017-11-29 2018-01-10 Kalvista Pharmaceuticals Ltd Solid forms of plasma kallikrein inhibitor and salts thereof
GB201910116D0 (en) * 2019-07-15 2019-08-28 Kalvista Pharmaceuticals Ltd Treatments of hereditary angioedema
WO2021028645A1 (en) 2019-08-09 2021-02-18 Kalvista Pharmaceuticals Limited Plasma kallikrein inhibitors
WO2022084693A1 (en) * 2020-10-23 2022-04-28 Kalvista Pharmaceuticals Limited Treatments of angioedema
JP2024505596A (ja) * 2021-02-09 2024-02-06 カルビスタ・ファーマシューティカルズ・リミテッド 遺伝性血管性浮腫の治療
US20250281397A1 (en) 2022-04-27 2025-09-11 Kalvista Pharmaceuticals Limited Formulations of a plasma kallikrein inhibitor
CN116003386B (zh) * 2022-11-20 2024-03-26 药康众拓(北京)医药科技有限公司 一种氘代n-苄基吡啶酮吡唑甲酰胺类化合物、药物组合物和用途
WO2025172693A1 (en) 2024-02-13 2025-08-21 Kalvista Pharmaceuticals Limited Oral sebetralstat for the treatment of an attack of hereditary angioedema
WO2025172692A1 (en) 2024-02-13 2025-08-21 Kalvista Pharmaceuticals Limited Oral sebetralstat for the treatment of an attack of hereditary angioedema
WO2026003532A1 (en) 2024-06-28 2026-01-02 Kalvista Pharmaceuticals Limited Sebetralstat for the treatment of anxiety associated with hereditary angioedema

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019106361A1 (en) * 2017-11-29 2019-06-06 Kalvista Pharmaceuticals Limited Dosage forms comprising a plasma kallikrein inhibitor

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5187157A (en) 1987-06-05 1993-02-16 Du Pont Merck Pharmaceutical Company Peptide boronic acid inhibitors of trypsin-like proteases
GB9019558D0 (en) 1990-09-07 1990-10-24 Szelke Michael Enzyme inhibitors
SE9301911D0 (sv) 1993-06-03 1993-06-03 Ab Astra New peptide derivatives
US5589467A (en) 1993-09-17 1996-12-31 Novo Nordisk A/S 2,5',N6-trisubstituted adenosine derivatives
GB0205527D0 (en) 2002-03-08 2002-04-24 Ferring Bv Inhibitors
US7429604B2 (en) 2004-06-15 2008-09-30 Bristol Myers Squibb Company Six-membered heterocycles useful as serine protease inhibitors
EP2051707B1 (en) 2006-07-31 2013-07-17 Activesite Pharmaceuticals, Inc. Inhibitors of plasma kallikrein
DE102006050672A1 (de) 2006-10-24 2008-04-30 Curacyte Discovery Gmbh Hemmstoffe des Plasmins und des Plasmakallikreins
JP2013121919A (ja) 2010-03-25 2013-06-20 Astellas Pharma Inc 血漿カリクレイン阻害剤
ES2483802T3 (es) 2010-07-07 2014-08-07 The Medicines Company (Leipzig) Gmbh Inhibidores de serina proteasa
EP2595986A2 (en) 2010-07-14 2013-05-29 Addex Pharma SA Novel 2-amino-4-pyrazolyl-thiazole derivatives and their use as allosteric modulators of metabotropic glutamate receptors
US9290485B2 (en) 2010-08-04 2016-03-22 Novartis Ag N-((6-amino-pyridin-3-yl)methyl)-heteroaryl-carboxamides
GB2494851A (en) 2011-07-07 2013-03-27 Kalvista Pharmaceuticals Ltd Plasma kallikrein inhibitors
GB201300304D0 (en) 2013-01-08 2013-02-20 Kalvista Pharmaceuticals Ltd Benzylamine derivatives
RU2712621C2 (ru) 2013-05-23 2020-01-30 Калвиста Фармасьютикалз Лимитед Азотсодержащие гетероциклические производные, полезные в качестве ингибитора калликреина плазмы
EP2815749A1 (en) * 2013-06-20 2014-12-24 IP Gesellschaft für Management mbH Solid form of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione having specified X-ray diffraction pattern
EP2886107A1 (en) * 2013-12-17 2015-06-24 ObsEva S.A. Oral formulations of pyrrolydine derivatives
GB201421083D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd Enzyme inhibitors
GB201609607D0 (en) * 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts
GB201910116D0 (en) * 2019-07-15 2019-08-28 Kalvista Pharmaceuticals Ltd Treatments of hereditary angioedema

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019106361A1 (en) * 2017-11-29 2019-06-06 Kalvista Pharmaceuticals Limited Dosage forms comprising a plasma kallikrein inhibitor

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Expert Opinion on Biological Therapy, 2019, 19(6), 517-526*

Also Published As

Publication number Publication date
CN114126612A (zh) 2022-03-01
TW202112370A (zh) 2021-04-01
MD3982960T2 (ro) 2023-12-31
MX2021014557A (es) 2022-01-11
EP4282474A3 (en) 2024-02-14
DK3982960T3 (da) 2023-08-21
MA56187B1 (fr) 2023-09-27
JP2022536287A (ja) 2022-08-15
US20220218680A1 (en) 2022-07-14
PL3982960T3 (pl) 2024-01-15
HUE063163T2 (hu) 2023-12-28
JP7688078B2 (ja) 2025-06-03
CL2023000639A1 (es) 2023-10-30
SMT202300261T1 (it) 2023-09-06
KR20220024220A (ko) 2022-03-03
LT3982960T (lt) 2023-08-25
HRP20230696T1 (hr) 2023-10-13
RS64412B1 (sr) 2023-09-29
WO2020249977A1 (en) 2020-12-17
GB201910116D0 (en) 2019-08-28
EP3982960A1 (en) 2022-04-20
IL288615A (en) 2022-02-01
NZ782935A (en) 2025-02-28
ZA202110685B (en) 2024-06-26
SI3982960T1 (sl) 2023-10-30
US20260199312A1 (en) 2026-07-16
JP2023166406A (ja) 2023-11-21
ES2956471T3 (es) 2023-12-21
PH12021552966A1 (en) 2022-07-25
MY205687A (en) 2024-11-06
CA3142218A1 (en) 2020-12-17
CL2021003244A1 (es) 2022-09-30
UA129869C2 (uk) 2025-08-27
JP7356518B2 (ja) 2023-10-04
BR112021024664A2 (pt) 2022-05-31
EP3982960B1 (en) 2023-06-28
EP4282474A2 (en) 2023-11-29
AU2020293614B2 (en) 2024-08-15
AR119158A1 (es) 2021-12-01
FI3982960T3 (fi) 2023-08-29
EA202193019A1 (ru) 2022-03-24
JP2025124716A (ja) 2025-08-26
PT3982960T (pt) 2023-09-26
AU2020293614A1 (en) 2022-01-27
SG11202113304YA (en) 2021-12-30
MA56187A (fr) 2022-04-20

Similar Documents

Publication Publication Date Title
JP7688078B2 (ja) 遺伝性血管性浮腫の治療
JP7640474B2 (ja) 血管性浮腫の治療
US20240122909A1 (en) Treatments of hereditary angioedema
US20230381162A1 (en) Treatments of angioedema
JP2025514861A (ja) 血漿カリクレイン阻害剤の製剤
HK40101443A (en) Treatments of hereditary angioedema
EA048676B1 (ru) Лечение наследственного ангионевротического отека
HK40070596A (en) Treatments of hereditary angioedema
HK40070596B (en) Treatments of hereditary angioedema
JP2022069377A (ja) 血管性浮腫の処置
EP4673437A1 (en) New solid form of a plasma kallikrein inhibitor
WO2025172693A1 (en) Oral sebetralstat for the treatment of an attack of hereditary angioedema
WO2025172692A1 (en) Oral sebetralstat for the treatment of an attack of hereditary angioedema
KR102553153B1 (ko) 포유류에서 질환을 치료하기 위한 신규한 다중표적 약물

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20211230

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20230704

Patent event code: PE09021S01D

E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

Comment text: Final Notice of Reason for Refusal

Patent event date: 20231106

Patent event code: PE09021S02D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20240529

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20231106

Comment text: Final Notice of Reason for Refusal

Patent event code: PE06011S02I

Patent event date: 20230704

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

AMND Amendment
PX0901 Re-examination

Patent event code: PX09012R01I

Patent event date: 20240930

Comment text: Amendment to Specification, etc.

PX0701 Decision of registration after re-examination

Patent event date: 20241128

Comment text: Decision to Grant Registration

Patent event code: PX07013S01D

X701 Decision to grant (after re-examination)
GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20241226

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20241226

End annual number: 3

Start annual number: 1

PG1601 Publication of registration